透析療法ネクスト　XVII

出版社： 医学図書出版
著者：
発行日： 2014-06-15
分野： 臨床医学：内科  >  腎臓
ISBN： 9784865170641
電子書籍版： 2014-06-15
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,860 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,430 円(税込)

購入する

目次

  • 透析療法ネクスト　XVII

    ―目次―

    座談会
    　透析療法におけるカルニチン投与の意義

    特集　透析患者におけるカルニチン補充療法について
    　カルニチン療法の歴史的背景と
    　　わが国でのL体カルニチン製剤の販売経緯
    　血液透析患者におけるカルニチン欠乏と酸化ストレス
    　　―AGEs軽減作用への期待―
    　透析患者の貧血とカルニチン補充療法
    　透析患者の栄養障害とカルニチン補充療法
    　　―ビタミンD3、亜鉛、およびカルニチン補充の臨床経験―
    　透析患者の筋肉症状とカルニチン補充療法
    　透析患者の筋肉症状とカルニチン補充療法
    　　コメディカルの立場から
    　透析患者の疲労
    　透析患者の低血圧とカルニチン補充療法
    　透析患者の心血管疾患とカルニチン補充への期待
    　循環器疾患とカルニチン欠乏
    　　―左室駆出率が保持された心不全（HFpEF）における
    　　　カルニチンへの期待―
    　小児腹膜透析とカルニチン
    　HD・HDF治療とカルニチンの動態について
    　透析患者のカルニチン補充療法の可能性と課題
    　透析療法の歴史（17）透析導入における適応基準の変遷
    　　―主として成人血液透析療法の導入に関して―

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

座談会

P.8 掲載の参考文献
1) 櫻林耐他 : 日本透析医会雑誌 15 (2), 245-255, 2000
 
2) Wanner C et al : Kidney Int 32 (suppl 22), S132-135, 1987
 
3) Hurot JM et al : J Am Soc Nephrol 13 (3), 708-714, 2002
PubMed
4) Zhang Y et al : Am J Kidney Dis 44 (5), 866-876, 2004
PubMed
5) Lynch KE et al : Am J Kidney Dis 52 (5), 962-971, 2008
PubMed
6) Sakurabayashi T et al : Circ J 72 (6), 926-931, 2008
PubMed
7) Sakurabayashi T et al : Am J Nephrol 19 (4), 480-484, 1999
 
8) Moroi M et al : Am J Kidney Dis 61 (3), 466-475, 2013
PubMed
9) Cal6 LA et al : Int J Cardiol 107 (1), 54-60, 2006
 
10) Evans A : Am J Kidney Dis 41 (4 Suppl 4), S13-26, 2003
 
11) Adams SH et al : J Nutr 139 (6), 1073-1081, 2009
PubMed
12) Koeth RA et al : Nat Med 19 (5), 576-585, 2013
 
13) www.nbcnews.com/video/nightly-news/51472670 2013/04/08
 
14) McCarty MF et al : Mayo Clin Proc 88 (8), 786-789, 2013
PubMed
15) Li JL et al : J Biomed Sci 19 (1), Article No. 32, 2012
 
16) Duranay M et al : Nephrol Dial Transplant 21 (11), 3211・3214, 2006
 
17) Shakeri A et al : Hemodial lnt 14 (4), 498-504, 2010
 
18) Chen Y et al l Am J Clin Nutr 99 (2), 408-422, 2014
 
19) Adachi T et al : Nephrology (Carlton) 17 (8), 689-694, 2012
PubMed
20) Savica V : JRen Nutr 15 (2), 225-230, 2005
 
21) 櫻林耐 : 日本透析医会雑誌 27 (2), 294-300, 2012
 
22) Murphy WJ et al : Nephrol Dial Transplant 27 (1), 304-310, 2012
PubMed

特集 透析患者におけるカルニチン補充療法について

P.11 掲載の参考文献
1) Bremer J : Carnitine-metabolism and functions. Physiol Rev 63 : 1420-1480, 1983
PubMed
2) Reuter SE, Evans AM : Carnitine and acylcarnitines : pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet 51 : 553-572, 2012
PubMed
3) Engel AG, Angelini C : Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy : a new syndrome. Science 179 : 899-902, 1973
PubMed
4) DiMauro S, DiMauro PM : Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science 182 : 929-931, 1973
PubMed
5) Willner JH, Chutorian AM, DiMauro S : Tissue carnitine in Reye syndrome. Ann Neurol 4 : 468-469, 1978
PubMed
6) Sugiyama N, Morishita H, Nagaya S, et al : Biochemical evidence of carnitine effect on propionate elimination. J Inherit Metab Dis 7 : 137-138, 1984
PubMed
7) 杉山成司, 松田一郎, 和田義郎, 他 : 全国19施設のプロピオン酸血症, ビタミンB12反応性及び不応性メチルマロン酸血症における塩化レボカルニチン (L-カルニチン) の効果について (1) 臨床的評価, 日児誌 93 : 1808-1817, 1989
 
8) De Vivo DC, Bohan TP, Coulter DL, et al : L-carnitine supplementation in childhood epilepsy : current perspectives. Epilepsia 39 : 1216-1225, 1998
PubMed
9) Ito T, Sugiyama N, Kobayashi M, et al : Alteration of ammonia and carnitine levels in short-term treatment with pivalic acid-containing Prodrug. Tohoku J Exp Med 175 : 43-53, 1995
PubMed
10) 伊藤進, 吉川徳茂, 板橋家頭夫, 他 (日本小児科学会薬事委員会) : ピボキシル基含有抗菌薬投与による二次性カルニチン欠乏症への注意喚起. 日児誌 116 : 804-806, 2012
 
11) Makino Y, Sugiura T, Ito T, et al : Carnitine-associated encephalopathy caused by long-term treatment with an antibiotic containing pivalic acid. Pediatrics 120 : e739-741, 2007
PubMed
12) Evangeliou A, Vlassopoulos D : Carnitine metabolism and deficit-when supplementation is necessary? Curr Pharm Biotechnol 4 : 211-219, 2003
PubMed
P.19 掲載の参考文献
1) Morena M, Patrier L, Jaussent I, et al : Reduced glomerular filtration rate, inflammation and hdl cholesterol as main determinants of superoxide production in non-dialysis chronic kidney disease patients, Free Radic Res 45 : 735-745, 2011
PubMed
2) Coombes JS, Fassett RG : Antioxidant therapy in hemodialysis patients : A systematic review. Kidney Int 81 : 233-246, 2012
PubMed
3) Coughlan MT, Thorburn DR, Penfold SA, et al : Rage-induced cytosolic ros promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20 : 742-752, 2009
PubMed
4) Savica V, Santoro D, Mazzaglia G, et al : L-carnitine infusions may suppress serum creactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr 15 : 225-230, 2005
PubMed
5) Tabibi H, Hakeshzadeh F, Hedayati M, et al : Effects of l-carnitine supplement on serum amyloid a and vascular inflammation markers in hemodialysis patients : A randomized controlled trial. J Ren Nutr 21 : 485-491, 2011
PubMed
6) Vesela E, Racek J, Trefil L, et al : Effect of l-carnitine supPlementation in hemodialysis patients. Nephron 88 : 218-223, 2001
PubMed
7) Fatouros IG, Douroudos I, Panagoutsos S, et al : Effects of l-carnitine on oxidative stress responses in patients with renal disease. Med Sci Sports Exerc 42 : 1809-1818, 2010
PubMed
8) Kaida Y, Fukami K, Matsui T, et al : Dna aptamer raised against ages blocks the progression of experimental diabetic nephropathy. Diabetes 62 : 3241-3250, 2013
PubMed
9) Genuth S, Sun W, Cleary P, et al : Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54 : 3103-3111, 2005
PubMed
10) den Dekker MA, Zwiers M, van den Heuvel ER, et al : Skin autofluorescence, a non-invasive marker for age accumulation, is associated with the degree of atherosclerosis. PLoS One 8 : e83084, 2013
PubMed
11) Meerwaldt R, Hartog JW, Graaff R, et al : Skin autofiuorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16 : 3687-3693, 2005
PubMed
12) Nagano M, Fukami K, Yamagishi S, et al : Tissue level of advanced glycation end products is an independent determinant of high-sensitivity c-reactive protein levels in haemodialysis patients. Nephrology (Carlton) 16 : 299-303, 2011
PubMed
13) Adachi T, Fukami K, Yamagishi S, et al : Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients. Nephrology (Carlton) 17 : 689-694, 2012
PubMed
14) Rajasekar P, Anuradha CV : L-carnitine inhibits protein glycation in vitro and in vivo : Evidence for a role in diabetic management. Acta Diabetol 44 : 83-90, 2007
PubMed
15) Balasaraswathi K, Rajasekar P, Anuradha CV : Changes in redox ratio and protein glycation in precataractous lens from fructose-fed rats : Effects of exogenous l-carnitine. Clin Exp Pharmacol Physiol 35 : 168-173, 2008
PubMed
P.29 掲載の参考文献
1) Pisoni RL, Brag9-Gresham JL, Young EW : Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 : 94-111, 2004
 
2) Leaf DE, Goldfarb DS : Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 75 : 15-24, 2009
PubMed
3) Labonia WD : L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 26 : 757-764, 1995
PubMed
4) Golper TA, Wolfson M, Ahmad S, et al : Multicenter trial of L-carnitine in maintenance hemodialysis patients. 1. Carnitine concentrations and lipid effects. Kidney Int 38 : 904-911, 1990
 
5) Hiatt WR, Koziol BJ, Shapiro JI, et al : Carnitine metabolism during exercise in patients on chronic hemodialysis. Kidney Int 41 : 1613-1619, 1992
PubMed
6) Kooistra MP, Struyvenberg A, van Es A : The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron 57 : 127-128, 1991
PubMed
7) Matsumura M, Hatakeyama S, Koni I, et al : Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron 72 : 574-578, 1996
PubMed
8) Arduini A, Gorbunov N, Arrigoni-Martelli E, et al : Effects of L-carnitine and its acetate and propionate esters on the molecular dynamics of human erythrocyte membrane. Biochim Biophys Acta 1146 ; 1146 : 229-235, 1993
 
9) Butterfield DA, Rangachari A : Acetylcarnitine increases membrane cytoskeletal protein-protein interactions. Life Sci 52 : 297-303, 1993
PubMed
10) Ramsay RR, Mancinelli G, Arduini A : Carnitine palmitoyltransferase in human erythrocyte membrane. Properties and malonyl-CoA sensitivity. Biochem J 275 : 685-688, 1991
PubMed
11) Arduini A, Rossi M, Mancinelli G, et al : Effect of L-carnitine and acetyl-L-carnitine on the human erythrocyte membrane stability and deformability. Life Sci 47 : 2395-2400, 1990
 
12) Arduini A, Mancinelli G, Radatti GL, et al : Role of carnitine and carnitine palmitoyl-transferase as integral components of the pathway for membrane phospholipid fatty acid turnover in intact human erythrocytes. J Biol Chem 267 : 12673-12681, 1992
PubMed
13) Arduini A, Tyurin V, Tyuruna Y, et al : Acyl-trafficking in membrane phospholipid fatty acid turnover : the transfer of fatty acid from the acyl-L-carnitine pool to membrane phospholipids in intact human erythrocytes. Biochem Biophys Res Commun 187 : 353-358, 1992
PubMed
14) Andrieu-Abadie N, Jaffrezou JP, Hatem S, et al : L-carnitine prevents dqxorubicin-induced apoptosis of cardiac myocytes : role of inhibition of ceramide generation. FASEB J 13 : 1501-1510, 1999
PubMed
15) Mutomba MC, Yuan H, Konyavko M, et al : Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine. FEBS Lett 478 : 19-25, 2000
 
16) Lang F, Gulbins E, Lerche H, et al : Eryptosis, a window to systemic disease. Cell Physiol Biochem 22 : 373-380, 2008
PubMed
17) Mandal D, Mazumder A, Das P, et al : Fas-, caspase 8-, and caspase 3-dependent signaling regulates the activity of the aminophospholipid translocase and phosphatidylserine externalization in human erythrocytes. J Biol Chem 280 : 39460-39467, 2005
PubMed
18) Arduini A, Bonomini M, Clutterbuck EJ, et al : Effect of L-carnitine administration on erythrocyte survival in haemodialysis patients. Nephrol Dial Transplant 21 : 2671-2672, 2006
PubMed
19) 水口隆, 北條千春, 金山恭子, 他 : 高容量の赤血球造血刺激因子製剤が必要な血液透析患者に対するL-カルニチン補充療法の効果 (赤血球寿命への効果も含めて). 透析会誌 47 : 191-197, 2014
 
20) Wanic-Kossowska M, Kazmierski M, Pawliczak E, et al : Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis. Pol Arch Med Wewn 117 : 14-19, 2007
 
21) Vlassopoulos DA, Hadjiyannakos DK, Anogiatis AG, et al : Carnitine action on red blood cell osmotic resistance in hemodialysis patients. J Nephrol 15 : 68-73, 2002
PubMed
22) Nikolaos S, George A, Telemachos T, et al : Effect of L-carnitine supplementation on red blood cells deformability in hemodialysis patients. Ren Fail 22 : 73-80, 2000
PubMed
23) Matsumura M, Hatakeyama S, Koni I, et al : Effect of L-carnitine and palmitoyl-Lcarnitine on erythroid colony formation in fetal mouse liver cell culture. Am J Nephrol 18 : 355-358, 1998
PubMed
24) Kitamura Y, Satoh K, Satoh T, et al : Effect of L-carnitine on erythroid colony formation in mouse bone marrow cells. Nephrol Dial Transplant 20 : 981-984, 2005
PubMed
25) Mutomba MC, Yuan H, Konyavko M, et al : Regulation of the activity of caspases by Lcarnitine and palmitoylcarnitine. FEBS Lett 478 : 19-25, 2000
 
26) De Maria R, Zeuner A, Eramo A, et al : Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 401 : 489-493, 1999
PubMed
27) Cald LA, Davis PA, Pagnin E, et al : Carnitine mediated improved response to erythropoietin involves induction of haem oxygenase-1 : studies in humans and in an animal model. Nephrol Dial Transplant 23 : 890-895, 2008
 
28) Albertazzi A, Capelli P, Di Paolo B, et al : Endocrine-metabolic effects of l-carnitine in patients on regular dialysis treatment. Proc Eur Dial Transplant Assoc 19 : 302-307, 1983
 
29) Trovato G, Ginardi V, Di Marco V, et al : Long-term L-carnitine treatment of chronic anaemia of patients with end-stage renal failure. Clin Ther Res 31 : 1042-1049, 1982
 
30) Vacha GM, Giorcelli G, Siliprandi N, et al : Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients : decisive role of low levels of highdensity lipoprotein-cholesterol. Am J Clin Nutr 38 : 532-540, 1983
PubMed
31) Bellinghieri G, Savica V, Mallamace A, et al : Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 38 : 523-531, 1983
PubMed
32) Nilsson-Ehle P, Cederblad G, Fagher B, et al : Plasma lipoprotein, liver function and glucose metabolism in haemodialysis patients. Lack of effect of L-carnitine supple-mentation. Scand J Clin Lab Inveat 45 : 179-184, 1985
 
33) Donatelli M, Terrizzi C, Zumro G, et al : Effects of L-carnitine on chronic anemia and adenosine triphosphate concentration in hemodialyzed patients. Curr Ther Res 41 : 621-624, 1987
 
34) B6rard E, Iordache A : Effect of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children : about two cases. Nephron 62 : 368-369, 1992
 
35) Labonia WD : L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 26 : 757-764, 1995
PubMed
36) Boran M, Dalva I, G6nenc F, et al : Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease. Nephron 73 : 314-315, 1996
 
37) Kavadias D, Fourtounas C, Tsouchnikas J, et al : L-carnitine and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis 28 : 156, 1996
PubMed
38) de los Reyes Bl, Navarro JA, Perez-Garcia R, et al : Effects of L-carnitine on erythrocyte acyl-CoA, free CoA, and glycerophospholipid acyltransferase in uremia. Am J Clin Nutr 67 : 386-390, 1998
PubMed
39) Trovato GM, Iannetti E, Murgo AM, et al : Body composition and long-term levo-carnitine supplementation. Clin Ter 149 : 209-214, 1998
PubMed
40) Caruso U, Leone L, Cravotto E, et al : Effects of L-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin : a pilot study. Dial Transplant 27 : 498-506, 1998
 
41) Kletzmayr J, Mayer G, Legenstein E, et al : Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int Suppl 69 : S93-106, 1999
PubMed
42) Nikolaos S, George A, Telemachos T, et al : Effect of L-carnitine supplementation on red blood cells deformability in hemodialysis patients. Ren Fail 22 : 73-80, 2000
PubMed
43) Matsumoto Y, Amano I, Hirose S, et al : Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin. Blood Purif 19 : 24-32, 2001
 
44) Vesela E, Racek J, Trefil L, et al : Effect of L-carnitine supplementation in hemodialysis patients. Nephron 88 : 218-223, 2001
PubMed
45) Vaux EC, Taylor DJ, Altmann P, et al : Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Nephron Clin Pract 97 : c41-48, 2004
PubMed
46) Kadiroglu AK, Yilmaz ME, Sit D, et al : The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients. Ren Fail 27 : 367-372, 2005
PubMed
47) Mitwalli AH, AI-Wakeel JS, Alam A, et al : L-Carnitine supplementation in hemodialysis patients. Saudi J Kidney Dis Transplant 16 : 17-22, 2005
 
48) Savica V, Santoro D, Mazzaglia G, et al : L-carnitine infusions may suppress serum C reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr 15 : 225-230, 2005
 
49) Hurot JM, Cucherat M, Haugh M, et al : Effects of L-carnitine supplementation in maintenance hemodialysis patients : a systematic review. J Am Soc Nephrol 13 : 708-714, 2002
PubMed
50) Evans A : Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis 41 (4 Suppl 4) : S13-26, 2013
 
51) 水口隆 : ESA治療低反応性. 透析会誌 27 : 138-147, 2012
 
52) 2008年版日本透析医学会 : 慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌 41 : 661-716, 2008
 
P.42 掲載の参考文献
1) 日本透析医学会 : 図説わが国の慢性透析療法の現況2012年12月31日現在. 47-57, 2013
 
2) 伊達敏行, 重松隆林恭子, 他 : 静注ビタミンD3パルス療法の腎性貧血改善効果とその機序に関する臨床的検討. 臨床透析 27 : 743-748, 2001
 
3) Sim JJ, Lac PT, Liu IL, et al : Vitamin D deficiency and anemia : a cross-sectional study. Ann Hematol 201 : 447-452, 2010
 
4) Argiles A, Lorho R, Mourad G, et al : High-dose alfacalcidol for anemia in dialysis. Lancet 342 : 378-379, 1993
PubMed
5) Albitar S, Genin R, Fen-Chong M, et al : High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol Dial Transplant 12 : 514-518, 1997
PubMed
6) Goicoechea M, Vazquez MI, Riiz MA, et al : Intravenous calcitriol improves anemia and reduces the need for erythropoietin in haemodialysis patients. Nephron 78 : 23-27, 1998
 
7) Aucella F, Scalzulli RP, Gatta G, et al : Calcitriol increases burst forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEpo. Nephron Clin Pract 95 : c121-c127, 2003
 
8) Deicher R, Horl WH : Hormonal adjuvants for the treatment of renal anemia. Eur J Clin Invest 35 : 75-84, 2005
PubMed
9) Patel NM, Gutierrez OM, Andress DL, et al : Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 77 : 715-720, 2010
PubMed
10) Kanbay M, Perazella M, Kasapoglu B, et al : Erythropoiesis stimulatory agent-resistant anemia in dialysis patients : revew of causes and management. Blood Purif 29 : 1-12, 2010
 
11) Shoji T, Shinohara K, Kimoto E, et al : Lower risk for cardiovascular mortality in oral 1 alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19 : 179-184, 2004
 
12) Gorham ED, Garland CF, Garland FC, et al : Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 97 : 179-194, 2005
PubMed
13) Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, et al : Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 10 : 185-197, 2008
PubMed
14) Li YC, Kong J, Wei M, et al : 1, 25-Dihydroxyvitamin D is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110 : 229-238, 2002
PubMed
15) Levin A, Li YC : Vitamin D and its analogues : do they protect against cardiovasucular disease in patients with kidney disease? Kidney Int 68 : 1973-1981, 2005
 
16) Carvalho C, Isakova T, Collerone G, et al : Hepcidin and disordered mineral metabolism in chronic kidney disease. Clin Nephrol 76 : 90-98, 2011
PubMed
17) Icardi A, Paoletti E, Nicola LD, et al : Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency : the potential role of inflammation. Nephrol Dial Transplant 28 : 1672-1679, 2013
 
18) Hurot JM, Cucherat M, Haug M, et al : Effects of L-carnitine supplernentation in maintenance hemodialysis patients : A systemic review. Clin J Am Soc Nephrol 13 : 708-714, 2002
 
19) Kletzmayr J, Mayer G, Legenstein E, et al : Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int 69 : S93-S106, 1999
PubMed
20) Nikolaos S, George A, Telemachos T, et al : Effect of L-carnitine supplementation on red blood cells deformability in hemodialysis patients. Renal Fail 22 : 73-80, 2000
PubMed
21) Vlassopoulos DA, Hadjiyannakos DK, Anogiatis AG, et al : Carnitine action on red blood cell osmotic resistance in hemodialysis patients. J Nephrol 15 : 68-73, 2002
PubMed
22) Arduini A, Mancinelli G, Radatti GL, et al : Role of carnitine and carnitine palmitoyltransferase an integral components of the pathway of membrane ppspholipid fatty acid turnover in intact human erythrocytes. JBiol Chem 267 : 12673-12681, 1992
 
23) Bonomini M, Zammit V, Pusey CD, et al : Pharmacological use of L-carnitine in uremic Anemia : Has its full potential been exploited? Pharmacological Research 63 : 157-164, 2011
PubMed
24) Brass EP, Aldler S, Sietsema KE, et al : Intravenous L-Carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 37 : 1018-1028, 2001
 
25) Nishiyama S, Inomoto T, Nakamura T, et al : Zinc status to hematological deficits in women endurance runners. J Am Coll Nutr 15 : 359-363, 1996
PubMed
26) Xia J, Browning JD, O'Dell BL : Decreased plasma menbrane thiol concentration is associated with increased osmotic fragility of erythrocyte in zinc-deficient rats. J Nutr 129 : 814-819, 1999
 
27) Fukushima T, Horiike H, Fujiki S, et al : Zinc deficiency anemia and effect of zinc therapy in meintanance hemodialysis patients. Therapeu Apheresis Dialysis 13 : 213-219, 2009
 
28) 飛田知子, 水口隆, 三木良昭, 他 : 亜鉛欠乏症によるエリスロポエチン抵抗性の腎性貧血. 臨床透析 20 : 1229-1232, 2004
 
29) 岩崎滋樹 : 亜鉛 (Zn) と貧血. 臨床透析 20 : 1173-1177, 2004
 
30) 瀬崎良三, 中島貴, 杉浦泰造, 他 : 亜鉛の経口投与が維持透析患者の貧血に及ぼす効果. Ther Res 28 : 1711-1715, 2007
 
P.53 掲載の参考文献
1) Debska-Slizien A, Kawecka A, Wojnarowski K, et al : Carnitine Content in Different muscles of patients receiving maintenance hemodialysis. J Ren Nutr 17 : 275-281, 2007
PubMed
2) Evans AM, Faull RJ, Nation RL, et al : Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease. Kidney Int 66 : 1527-1534, 2004
PubMed
3) Giovenali P, Fenocchio D, Montanari G, et al : Selective trophic effect of L-carnitine in type I and II skeletal muscle fibers. Kidney Int 46 : 1616-1619, 1994
PubMed
4) Siami G, Clinton ME, Mrak R, et al : Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron 54 : 306-313, 1991
 
5) Lewis MI, Foumier M, Wang H, et al : Metabolic and morphometric profile of muscle fibers in chronic hemodialysis patients. J Appl Physiol 112 : 72-78, 2012
 
6) Lynch KE, Feldman HI, Berlin JA, et al : Effects of L-carnitine on dialysis-related hypotension and muscle cramps : ameta-analysis. Am J Kidney Dis 52 : 962-971, 2008
 
7) Ahmad S, Robertson HT, Golper TA, et al : Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 38 : 912-918, 1990
PubMed
8) Casciani CU, Caruso U, Cravotto E, et al : Beneficial effects of L-carnitine in post-dialysis syndrome. Curr Ther Res 32 : 116-127, 1982
 
9) Bellinghieri G, Savica V, Mallamace A, et al : Correlation between increased serum and tissue L-carinitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 38 : 523-534, 1983
 
10) Sakurauchi Y, Matsumoto Y, Shinzato T, et al : Effects of Lcarnitine supplementation on muscular symptoms in hemodialyzed patients. Am J Kidney Dis 32 : 258-264, 1998
PubMed
11) 武内操, 清原実千代, 町田博文, 他 : 血液透析患者に対するレボカルニチン補充療法. 透析会誌 45 : 955-963, 2012
 
12) Hiatt WR, Koziol BJ, Shapiro JI, et al : Carnitine metabolism during exercise in patients on chronic hemodialysis. Kidney Int 41 : 1613-1619, 1992
PubMed
13) Steiber AL, Davis AT, Spry L, et al : Carnitine treatment improved quality-of-life measure in a sample of Midwestern hemodialysis patients. JPEN J parenter Enteral Nutr 30 : 10-15, 2006
 
P.63 掲載の参考文献
1) Casciani CU, Caruso U, Cravotto E, et al : Beneficial effects of L-carnitine in post-dialysis syndrome. Curr Ther Res 32 : 116-127, 1982
 
2) Lynch KE, Feldman HI, Berlin JA, et al : Effects of L-carnitine on dialysis-related hypotension and muscle cramps : A meta-analysis. Am J Kidney Dis 52 : 962-971, 2008
PubMed
3) 坂本和也, 熊谷文昭, 櫛田隆久, 他 : 維持透析患者における筋症状の実態. 透析会誌 45 (Suppl 1) : 487, 2012
 
P.70 掲載の参考文献
1) Jhamb M, Weisbord SD, Steel JL, et al : Fatigue in patients receiving maintenance dialysis : a review of definitions, measures, and contributing factors. Am J Kidney Dis 52 : 353-365, 2008
PubMed
2) Weisbord SD, Fried LF, Arnold RM, et al : Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 16 : 2487-2494, 2005
PubMed
3) Unruh M, Benz R, Greene T, et al : Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int 66 : 355-366, 2004
PubMed
4) Chang WK, Hung KY, Huang JW, et al : Chronic fatigue in long-term peritoneal dialysis patients. Am J Nephrol 21 : 479-485, 2001
PubMed
5) Weisbord SD, Fried LF, Mor MK, et al : Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol 2 : 960-967, 2007
PubMed
6) Lindsay RM, Heidenheim PA, Nesrallah G, et al : Minutes to recovery after a hemodialysis session : a simple health-related quality of life question that is reliable, valid, and sensitive to change. Clin J Am Soc Nephrol 1 : 952-959, 2006
 
7) 西沢良記 : 1 健康・良質な長寿と透析患者. 3. 腎不全における代謝異常と良質な長寿-透析患者の慢性疲労研究を踏まえて-. In 最新透析医学 西沢良記, Ed. 医薬ジャーナル社, 大阪, p28-36, 2008
 
8) Fukuda S, Takashima S, Iwase M, et al : Development and validation of a new fatigue scale for fatigued subjects with and without chronic fatigue syndrome. In Fatigue science for human health Watanabe Y, Evengard B, Natelson BH, Jason LA, Kuratsune H, Eds. Springer, New York, p89-102, 2008
 
9) Koyama H, Fukuda S, Shoji T, et al : Fatigue is a predictor for cardiovascular outcomes in patients undergoing hemodialysis. Clin J Am Soc Nephrol 5 : 659-666, 2010
PubMed
10) Brass EP, Adler S, Sietsema KE, et al : Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 37 : 1018-1028, 2001
PubMed
11) Wu AW, Fink NE, Marsh-Manzi JV, et al : Changes in quality of life during hemodialysis and peritoneal dialysis treatment : generic and disease specific measures. J Am Soc Nephrol 15 : 743-753, 2004
 
12) Suri RS, Nesrallah GE, Mainra R, et al : Daily hemodialysis : a systematic review. Clin J Am Soc Nephrol 1 : 33-42, 2006
PubMed
13) Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al : Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11 : 335-342, 2000
 
14) Jones M, Ibels L, Schenkel B, et al : Impact of epoetin alfa on clinical end points in patients with chronic renal failure : a meta-analysis. Kidney Int 65 : 757-767, 2004
PubMed
15) Singh AK, Szczech L, Tang KL, et al : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 : 2085-2098, 2006
PubMed
16) Pecoits-Filho R, Lindholm B, Stenvinkel P : The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant 17 (Suppl 11) : 28-31, 2002
 
17) Bergstrom J, Lindholm B, Lacson E, et al : What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 13 : 163-175, 2000
 
18) Memoli B, Libetta C, Rampino T, et al : Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney Int 42 : 320-326, 1992
PubMed
19) Balakrishnan VS, Guo D, Rao M, et al : Cytokine gene polymorphisms in hemodialysis patients : association with comorbidity, functionality, and serum albumin. Kidney Int 65 : 1449-1460, 2004
PubMed
20) Kamimura MA, Draibe SA, Dalboni MA, et al : Serum and cellular interleukin-6 in haemodiaiysis patients : relationship with energy expenditure. Nephrol Dial Transplant 22 : 839-844, 2007
PubMed
21) Sklar A, Newman N, Scott R, et al : Identification of factors responsible for postdialysis fatigue. Am J Kidney Dis 34 : 464-470, 1999
PubMed
22) Heidenheim AP, Muirhead N, Moist L, et al : Patient quality of life on quotidian hemodialysis. Am J Kidney Dis 42 : 36-41, 2003
PubMed
23) Unruh ML, Levey AS, D'Ambrosio C, et al : Restless legs symptoms among incident dialysis patients : association with lower quality of life and shorter survival. Am J Kidney Dis 43 : 900-909, 2004
PubMed
24) Merlino G, Piani A, Dolso P, et al : Sleep disorders in patients with end-stage renal disease undergoing dialysis therapy. Nephrol Dial Transplant 21 : 184-190, 2006
PubMed
25) Sanner BM, Tepel M, Esser M, et al : Sleeprelated breathing disorders impair quality of life in haemodialysis recipients. Nephrol Dial Transplant 17 : 1260-1265, 2002
PubMed
26) Unruh ML, Buysse DJ, Dew MA, et al : Sleep quality and its correlates in the first year of dialysis. Clin J Am Soc Nephrol 1 : 802-810, 2006
PubMed
27) Yang JY, Huang JW, Chiang CK, et al : Higher plasma interleukin-18 levels associated with poor quality of sleep in peritoneal dialysis patients. Nephrol Dial Transplant 22 : 3606-3609, 2007
PubMed
28) Watnick S, Kirwin P, Mahnensmith R, et al : The prevalence and treatment of depression among Patients starting dialysis. Am J Kidney Dis 41 : 105-110, 2003
PubMed
29) Hedayati SS, Bosworth HB, Kuchibhatla M, et al : The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int 69 : 1662-1668, 2006
PubMed
30) Barron HV, Lesh MD : Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol 27 : 1053-1060, 1996
PubMed
31) Fukuta H, Hayano J, Ishihara S, et al : Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Nephrol Dial Transplant 18 : 318-325, 2003
PubMed
32) Nishimura M, Hashimoto T, Kobayashi H, et al : Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in diabetic haemodialysis patients. Nephrol Dial Transplant 19 : 2532-2538, 2004
 
33) Vita G, Bellinghieri G, Trusso A, et al : Uremic autonomic neuropathy studied by spectral analysis of heart rate. Kidney Int 56 : 232-237, 1999
PubMed
34) Ranpuria R, HaU M, Chan CT, et al : Heart rate variability (HRV) in kidney failure : measurement and consequences of reduced HRV. Nephrol Dial Transplant 23 : 444-449, 2008
 
35) Fujii H, Koyama H, Fukuda S, et al : Autonomic function is associated with health-related quality of life in patients with endstage renal disease : acase-control study. J Ren Nutr 23 340-347, 2013
 
P.78 掲載の参考文献
1) Bohmer T, Rydning A, Solberg HG : Carnitine levels in human serum in health and disease. Clin Chim Acta 57 : 55-61, 1974
 
2) Bohmer T, Bergrem H, Eiklid K : Carnitine deficiency induced during intermittent hemodialysis for renal failure. Lancet 1 : 126-128, 1978
PubMed
3) Bertoli M, Battistella PA, Vergani L, et al : Carnitine deficiency induced during hemodialysis and hyperlipidemia. Effect of replacement therapy. Am J Clin Nutr 34 : 1496-1500, 1981
PubMed
4) Engel AG : Possible causes and effects of carnitine deficiency in man. In Carnitine Biosynthesis, Metabolism, and Function, ed by Frenkel RA, Mcgarry JD, Academic Press, p271-285, 1980
 
5) Mingardi G, Bizzi A, Cini M, et al : Carnitine balance in hemodialyzed patients. Clin Nephrol 13 : 269-270, 1980
PubMed
6) Bartel LL, Hussey JL, Schrago E : Perturbation of serum carnitine levels in human adults by chronic renal disease and dialysis therapy. Am J Clin Nutr 34 : 1314-1320, 1981
 
7) Kudoh Y, Shoji T, Oimatsu H, et al : The role of l-carnitine in the pathogenesis of cardiomegaly in patients with chronic hemodialysis. Jpn Circ J 47 : 1391-1397, 1983
PubMed
8) Kudoh Y, Shoji T, Oimatsu H, et al : Study on the risk factors of ischemic heart disease in patients with chronic hemodialysis with special reference of the role of plasma l-carnitine. JPn J Nephrol 25 : 429-438, 1983
 
9) Fagher B, Cederblad G, Eriksson M, et al : Lcarnitine and haemodialysis : Double blind study on muscle function and metabolism and peripheral nerve function. Scand J Clin Lab Invest 45 : 169-178, 1985
PubMed
10) Bremer J : Carnitine metabolism and functions. Physiol Rev 63 : 1420-1480, 1983
PubMed
11) Brass EP : Carnitine transport. In ; Ferrari R, Di Mauro S, Sherwood WG, eds. L-carnitine and Its Role in Medicine : From Fuction to Therapy. London : Academic Press p21-36, 1992
 
12) Rebouche CJ, Engel AG : Kinetic compartment analysis of carnitine metabolism in the human carnitine deficiency syndrome. J Clin Invest 73 : 857-867, 1984
PubMed
13) Fornasini G, Upton RN, Evans AM : A pharmacokinetic model for 1-carnitine in patients receiving haemodialysis. Br J Clin Pharmacol 64 : 335-345, 2007
 
14) Vacha GM, Corsi M, Giorcelli G, et al : Serum and muscle l-carnitine levels in hemodialized patients, during and after long-term l-carnitine treatment. Curr Ther Res 37 : 505-513, 1985
 
15) Kudoh Y, Shoji T, Oimatsu H, et al : Plasma l-carnitine in patients with chronic hemodialysis. II. Pharmacokinetics of l-carnitine and its replacement therapy in these patients. Nihon Jinzo Gakkai Shi 26 : 57-64, 1984
 
16) Siami G, Clinton ME, Mrak R, et al : Evaluation of the effect intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron 57 : 306-313, 1991
 
17) Debska-Slizien A, Kawecka A, Wojnarowski K, et al : Correlation between plasma carnitine, muscle carnitine and glycogen levels in maintenance hemodialysis patients. Int J Artif Organs 23 : 90-96, 2000
 
18) Harper P, Elwin CE, Cederblad G : Pharmacokinetics of intravenous and oral bolus doses of l-carnitine in healthy subject. Eur J Clin Pharmacol 35 : 555-562, 1988
 
19) Brass EP : Pharmacokinetic considerations for the therapeutic use of catrnitine in hemodialysis patients. Clin Ther 17 : 176-185, 1995
PubMed
20) Evans A : Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis 41 : S13-26, 2003
PubMed
21) Horiuchi M, Yoshida H, Kobayashi K, et al : Cardiac hypertrophy in juvenile visceral steatosis (jvs) mice with systemic carnitine deficiency. FEBS 326 : 267-271, 1993
PubMed
22) Tripp ME, Katcher ML, Peters HA, et al : Systemic carnitine deficiency presenting as familial endocardial fibroelastosis. A treatable cardiomyopathy. N Engl J Med 305 : 385-390, 1981
PubMed
23) Fagher B, Cederblad G, Monti M, et al : Carnitine and left ventricular function in haemodialysis patients. Scand J Clin Lab Invest 45 : 193-198, 1985
PubMed
24) Kudoh Y, Satoh S, Tsuchida A, et al : The dual effects of hemodialysis on cardiac function assessed by pulsed doppler echocardiography. Jpn Circ J 52 : 13-20, 1988
PubMed
25) Kudoh Y, Aoyama S, Torii T, et al : Hemodynamic stabilizing effects of l-carnitine in chronic hemodialysis patients. Cardiorenal Med 3 : 200-207, 2013
PubMed
26) National Kidney Foundation : K/DoQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am L Kidney Dis 35 : S1-S140, 2000
 
27) Weinhandl ED, Rao M, Gilbertson DT, et al : Protective effect of intravenous levocarnitine on subsequent-month hospitalization among Prevalent hemodialysis patients, 1998 to 2003. Am J Kidney Dis 50 : 803-812, 2007
PubMed
28) Tisler A, Akocsi K, Borbas B, et al : The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis. Nephrol Dial Transplant 18 : 2601-2605, 2003
PubMed
29) Casciani CU, Caruso U, Cravotto E, et al : Beneficial effects of L-cranitine in post-dialysis syndrome. Curr Ther Res 32 : 116-127, 1982
 
30) Ahmad S, Robertson HT, Golper TA, et al : Multicenter trial of l-carnitine in maintenance of hemodialysis patients II. Clinical and biochemical effects. Kidney Int 38 : 912-918, 1990
PubMed
P.86 掲載の参考文献
1) Zoccali C, Benedetto FA, Tripepi G, et al : Left ventricular systolic function monitoring in asymptomatic dialysis patients : A prospective cohort study. J Am soc Nephrol 17 : 1460-1465, 2006
PubMed
2) Schreiber BD : Dabate Forum : Levocarnitine therapy is rational and justified in selected dialysis patients. Blood Purif 24 : 128-139, 2006
 
3) Wasserstein AG : L-carnitine supplementation in dialysis : Treatment in Quest of Disease. Semin Dial 26 : 11-15, 2013
PubMed
4) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (2012年12月31日現在). 日本透析医学会, 東京, p21-22, 2013
 
5) US Renal Data System : USRDS 2011 Annual Data Report. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011
 
6) 久保峻, 常喜信彦, 田中友里, 他 : 透析患者の心臓死を考える. 透析会誌 46 : 1157-1158, 2013
 
7) Opie LH, Hasenfuss G : Mechanisms of cardiac contraction and relaxation. In Bonow RO, Mann DL, Zipes DP, Libby P, editors. Braunwald's heart disease. Philadelphia : Elsevier, p487-504, 2012
 
8) Wasserstein A : Carnitine metabolism in renal disease and dialysis, Up To Date 2014
 
9) Eknoyan G, Latos DL, Lindberg J : National Kidney Foundation Carnitine Consensus Conference, Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. Am Kidney Dis 41 : 868-876, 2003
PubMed
10) Medicare Coverage Policy : Levocarnitine for end-stage renal disease decision memorandum, 2002
 
11) Matsumoto Y, Sato M, Ohashi H, et al : Effects of L-carnitine supPlementation on cardiac morbidity in hemodialyzed patients. Am J Nephrol 20 : 201-207, 2000
PubMed
12) Sakata Y, Ohtani T, Takeda Y, et al : Left ventricular stiffening as therapeutic target for heart failure with preserved ejection fraction. Circl J 77 : 886-892, 2013
 
P.96 掲載の参考文献
1) Tsuchihashi M, Hamaguchi S, Kinugawa S, et al : Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction-a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) -. Circ J 73 : 1893-1900, 2009
 
2) Solomon SD, Wang D, Finn P, et al : Effect of candesartan on cause-specific mortality in heart failure patients : the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 110 : 2180-2183, 2004
 
3) Remme WJ, Cleland JG, Erhardt L, et al : Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. Eur J Heart Fail 9 : 1128-1135, 2007
PubMed
4) Henkel DM, Redfield MM, Weston SA, et al : Death in heart failure : acommunity perspective. Circ Heart Fail 1 : 91-97, 2008
 
5) Zile MR, Gaasch WH, Anand IS, et al : Mode of death in patients with heart failure and a preserved ejection fraction : results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (1-Preserve) trial. Circulation 121 : 1393-1405, 2010
 
6) Hasin T, Gerber Y, McNallan SM, et al : Patients With Heart Failure Have an Increased Risk of Incident Cancer. J Am Coll Cardiol 62 : 881-886, 2013
 
7) Zile MR, Baicu CF, Gaasch WH : Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 : 1953-1959, 2004
PubMed
8) Dunlay SM, Roger VL, Weston SA, et al : Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 5 : 720-726, 2012
PubMed
9) van Heerebeek L, Borbely A, Niessen HWM, et al : Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113 : 1966-1973, 2006
PubMed
10) Borlaug BA, Redfield MM, Melenovsky V, et al : Longitudinal changes in left ventricular stiffness : a community-based study. Circ Heart Fail 6 : 944-952, 2013
PubMed
11) Kawaguchi M, Hay I, Fetics B, et al : Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction : implications for systolic and diastolic reserve limitations. Circulation 107 : 714-720, 2003
PubMed
12) Takeda Y, Sakata Y, Ohtani T, et al : Endovascular Aortic Repair Increases Vascular Stif [ness and Alters Cardiac Structure and Function. Circ J 78 : 322-328, 2014
 
13) Nishio M, Sakata Y, Mano T, et al : Difference of clinical characteristics between hypertensive patients with and without diastolic heart failure : role of diastolic dysfunction and renal insufficiency. Hypertens Res 31 : 1865-1872, 2008
 
14) Takeda Y, Sakata Y, Mano T, et al : Competing risks of heart failure with preserved ejection fraction in diabetic patients. Eur J Heart Fail 13 : 664-669, 2011
PubMed
15) Yusuf S, Pfeffer MA, Swedberg K, et al : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved Trial. Lancet 362 : 777-781, 2003
PubMed
16) Cleland JGF, Tendera M, Adamus J, et al : The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 : 2338-2345, 2006
PubMed
17) Massie BM, Carson PE, McMurray JJ, et al : Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 : 2456-2467, 2008
PubMed
18) Shah SJ, Heitner JF, Sweitzer NK, et al : Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 6 : 184-192, 2013
PubMed
19) Yamamoto K, Origasa H, Hori M : Effects of carvedilol on heart failure with preserved ejection fraction : the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15 : 110-118, 2013
PubMed
20) Dobre D, van Veldhuisen DJ, DeJongste MJ, et al : Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail 9 : 280-286, 2007
PubMed
21) Omori Y, Ohtani T, Sakata Y, et al : L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens 30 : 1834-1844, 2012
PubMed
22) DiNicolantonio JJ, Lavie CJ, Fares H, et al : L-carnitine in the secondary prevention of cardiovascular disease : systematic review and meta-analysis. Mayo Clin Proc 88 : 544-551, 2013
PubMed
23) Pierpont ME, Breningstall GN, Stanley CA, et al : Familial carnitine transporter defect : A treatable cause of cardiomyopathy in children. Am Heart J 139 : S96-S106, 2000
PubMed
24) Koeth RA, Wang Z, Levison BS, et al : Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19 : 576-585, 2013
 
25) Siri-Tarino PW, Sun Q, Hu FB, et al : Metaanalysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr 91 : 535-546, 2010
PubMed
P.105 掲載の参考文献
1) Ito T, Sugiyama N, Kobayashi M, et al : Alteration of ammonia and carnitine levels in short-term treatment with pivalic acid-containing Prodrug. Tohoku J Exp Med 175 : 43-53, 1995
PubMed
2) Nakajima Y, Ito T, Maeda Y, et al : Detection of pivaloylcarnitine in pediatric patients with hypocarnitinemia after long-term administration of pivalate-containing antibiotics. Tohoku J Exp Med 221 : 309-313, 2010
PubMed
3) Coulter DL : Carnitine deficiency in epilepsy : Risk factors and treatment. J Child Neurol 10 (Suppl 2) : S32-39, 1995
 
4) Nakajima Y, Ito T, Maeda Y, et al : Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS/MS. Brain Dev 33 : 816-823, 2011
 
5) 大谷宣伸 : 母乳および各種人工乳中のカルニチン含量について. 日児誌 88 : 1943-1949, 1984
 
6) Stanley CA : Carnitine deficiency disorders in children. Ann N Y Acad Sci 1033 : 42-51, 2004
PubMed
7) Gahl WA, Bernardini I, Dalakas M, et al : Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest 81 : 549-560, 1988
PubMed
8) 村上貴考, 杉本健郎, 西田直樹, 他 : カルニチン測定キットによる血清, 尿カルニチン血の検討. 小児内科 41 (増刊号) : 387-389, 1995
 
9) 高柳正樹 : カルニチンの臨床. 生物試料分析 35 : 281-292, 2012
Medical*Online
10) Belay B, Esteban-Cruciani N, Walsh CA, et al : The use of levo-carnitine in children with renal disease : a review and a call for future studies. Pediatr Nephrol 21 : 308-317, 2006
 
11) 上村治, 志水麻実子, 岩佐充二, 他 : 小児末期腎不全患者の血清カルニチン分画に与える生体腎移植の影響. 日小児会誌 103 : 869-870, 1999
 
12) Rebouche CJ, Paulson DJ : Carnitine metabolism and function in humans. Annu Rev Nutr 6 : 41-66, 1986
PubMed
13) Marin VB, Azocar M, Molina M, et al : Total carnitine and acylated carnitine ratio : relationship of free carnitine with lipid parameters in pediatric dialysis patients. Adv Perit Dial 22 : 130-135, 2006
PubMed
14) 川原和彦, 佐藤隆史, 川村研, 他 : 腹膜透析患児の心筋症に対するカルニチン投与の効果. 日小児腎不全会誌 15 : 224-227, 1995
 
15) Kudoh Y, Shoji T, Oimatsu H, et al : The role of L-carnitine in the pathogenesis of cardiomegaly in patients with chronic hemodialysis. JPn Circ J 47 : 1391-1397, 1983
PubMed
16) DiNicolantonio JJ, Lavie CJ, Fares H, et al : L-carnitine in the secondary prevention of cardiovascular disease : systematic review and meta-analysis. Mayo Clin Proc 88 : 544-551, 2013
PubMed
17) Gloggler A, Bulla M, FUrst P : Effect of low dose supplementation of L-carnitine on lipid metabolism in hemodialyzed children. Kidney Int 27 : S256-258, 1989
PubMed
18) Warady BA, Borum P, Stall C, et al : Carnitine status of pediatric patients on continuous ambulatory peritoneal dialysis. Am J Nephrol 10 : 109-114, 1990
PubMed
19) Zachwieja J, Duran M, Joles JA, et al : Amino acid and carnitine supPlementation in haemodialysed children. Pediatr Nephrol 8 : 739-743, 1994
PubMed
20) Kosan C, Sever L, Arisoy N, et al : Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients. Pediatr Nephrol 18 : 1184-1188, 2003
PubMed
21) Arduini A, Rossi M, Mancinelli G, et al : Effect of L-carnitine and acetyl-L-carnitine on the human erythrocyte membrane stability and deformability. Life Sci 47 : 2395-2400, 1990
 
22) Hedayati SS : Dialysis-related carnitine disorder. Semin Dial 19 : 323-328, 2006
 
23) Thomas S, Fischer FP, Mettang T, et al : Effects of L-carnitine on leukocyte function and viability in hemodialysis patients : A double-blind randomized trial. Am J Kidney Dis 34 : 678-687, 1999
PubMed
24) Matsumura M, Hatakeyama S, Koni I, et al : Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron 72 : 574-578, 1996
PubMed
25) Aoun B, B6rard E, Vitkevic R, et al : L-carnitine supplementation and EPO requirement in children on chronic hemodialysis. Pediatr Nephrol 25 : 557-560, 2010
 
26) Berard E, Iordache A : Effect of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children : about two cases. Nephron 62 : 368-369, 1992
PubMed
27) Lilien MR, Duran M, Quak JM, et al : Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis. Pediatr Nephrol 15 : 17-20, 2000
 
28) Uemura O, Goto Y, Iwasa M, et al : Secondary carnltine palmitoyltransferase deficiency in chronic renal failure and secondary hyperparathyroidism. Tohoku J Exp Med 178 : 307-314, 1996
PubMed
29) Evans A : Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis 41 : S13-26, 2003
PubMed
30) Reuter SE, Evans AM, Faull RJ, et al : Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease. Ann Clin Biochem 42 : 387-393, 2005
PubMed
31) Koeth RA, Wang Z, Levison BS, et al : Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19 : 576-585, 2013
 
32) Bonomini M, Pandolfi A, Di Liberato L, et al : L-carnitine is an osmotic agent suitable for peritoneal dialysis. Kidney Int 80 : 645-654, 2011
PubMed
P.111 掲載の参考文献
1) Lahjouji K, Mitchell GA, Qureshi IA : Carnitine transport by organic cation transporters and systemic carnitine deficiency. Mol Genet Metab 73 : 287-297, 2001
PubMed
2) Hoppel C : The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis 41 : S4-12, 2003
PubMed
3) Reuter SE, Faull RJ, Evans AM : L-carnitine supplementation in the dialysis population : are Australian patients missing out? Nephrology (Carlton) 13 : 3-16, 2008
PubMed
4) Leschke M, Rumpf KW, Eisenhauer T, et al : Quantitative assessment of carnitine loss during hemodialysis and hemofiltration. Kidney Int Suppl 16 : S143-146, 1983
PubMed
5) Rossle C, et al : Disturbed Carnitine metabolism in hemodialysis patients? Clinical nutrition (Suppl 5) : 136, 1986
 
6) Rodriguez-Segade S, Alonso de la Peia C, Paz JM, et al : Carnitine deficiency in haemodialysed patients. Clin Chim Acta 159 : 249-256, 1986
 
7) Lin YS, Yang WC, Chen TW, et al : Changes in the composition of carnitines in hemodialysis patients. Kidney Int 68 : 1368-1369, 2005
PubMed
8) Csiky B, Bene J, Wittmann I, et al : Effect of hemodialysis session on the dynamics of carnitine ester profile changes in L-carnitine pretreated end-stage renal disease patients. Int Urol Nephrol 45 : 847-855, 2013
 
P.121 掲載の参考文献
1) Maeda K Yoshida F, Shinzato T, et al : Effects of long-term D, L-carnitine administration on symptomatic hypotension during dialysis and hypotension outside of dialysis. Life Support System (Suppl 1) 2 : 146-148, 1984
 
2) Maeda K, Shizato T, Kobayakawa H : Effects of L-carnitine administration on short-chain fatty acid (acetic acid) and long-chain fatty acid metabolism during hemodialysis. Nephron 51 : 355-361, 1989
 
3) Kudoh Y, Aoyama S, Torii T, et al : Hemodynamic stabilizing effects of L-carnitine in chronic hemodialysis patients. Cardiorenal Med 3 : 200-207, 2013
PubMed
4) DiNicolantonio JJ, Lavie CJ, Fares H, et al : L-carnitine in secondary prevention of cardiovascular disease : systematic review and meta-analysis. Mayo Clin Proc 88 : 544-551, 2013
PubMed
5) Hurot JM, Cucherat M, Haugh M, et al : Effect of L-carnitine supplementation in maintenance hemodialysis patients : a systematic review. J Am Soc Nephrol 13 : 708-714, 2002
PubMed
6) Lynch KE, Feldman HI, Berlin JA, et al : Effect of L-carnitine on dialysis-related hypotension and muscle cramps : a meta-analysis. Am J Kiney Dis 52 : 962-971, 2008
 
7) Rizos I : Tree-years survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 239 : s120-s123, 2000
 
8) Moroi M, Tamaki N, Nishimura M, et al : Association between abnormal myocardial fatty acid metabolism and cardiac-derived death among patients undergoing hemodialysis : results from a cohort study in Japan. Am J Kidney Dis 61 : 466-475, 2013
PubMed
9) Sakurabayashi T, Miyazaki S, Yuasa Y, et al : L-carnitine supPlementation decreases the left ventricular mass in patients undergoing hemodialysis. Circ J 72 : 926-931, 2008
PubMed
10) Vesela E, Racek J, Trefil L, et al : Effect of L-carnitine supplementation in hemodialysis patients. Nephron 88 : 218-223, 2001
PubMed
11) Labonia WD : L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 26 : 757-764, 1995
PubMed
12) Calo LA, Davis PA, Pagnin E, et al : Carnitine-mediated improved response to erythropoietin involves induction of haem oxygenase-1 : studies in humans and in an animal model. Nephrol Dial Transplant 23 : 890-895, 2008
 
13) 櫻林耐 : 血液透析症例に対するLカルニチンの投与方法について. 透析会誌 27 : 294-300, 2012
 
14) Calo LA, Pagnin E, Davis PA, et al : Antioxidant effect of L-carnitine and its short chain esters relevance for the protection from oxidative stress related cardiovascular damage. International Journal of Cardiology 107 : 54-60, 2006
PubMed
15) Duranay M, Akay H, Meric F, et al : Effect of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant 21 : 3211-3214, 2006
 
16) Fonasini G, Upton RN, Evans AM : A pharmacokinetic model for L-carnitine in patients receiving haemodialysis. Br Clin Pharmacol 64 : 335-345, 2007
 

透析療法の歴史 ( 17 ) 透析導入における適応基準の変遷 - 主として成人血液透析療法の導入に関して -

P.135 掲載の参考文献
1) 中川成之輔, 他 : 透析の適応 : 日本臨床. 維持透析 39 : 9-13, 1981
 
2) 特集 腎代替療法の見直し. 腎と透析 73, 2012
Medical*Online
3) 特集 透析 (腎代替療法) 導入時期を考える. 臨床透析 28, 2012
 
4) 日本腎臓学会 : エビデンスに基づくCKD診療ガイドライン 2013
 
5) 日本透析医学会 : 血液透析導入ガイドライン (案) 2013
 

書評

最近チェックした商品履歴

Loading...